[go: up one dir, main page]

MX9803801A - Colagena de tipo ix y quimeras. - Google Patents

Colagena de tipo ix y quimeras.

Info

Publication number
MX9803801A
MX9803801A MX9803801A MX9803801A MX9803801A MX 9803801 A MX9803801 A MX 9803801A MX 9803801 A MX9803801 A MX 9803801A MX 9803801 A MX9803801 A MX 9803801A MX 9803801 A MX9803801 A MX 9803801A
Authority
MX
Mexico
Prior art keywords
type
collagen
collagens
chimeras
novel
Prior art date
Application number
MX9803801A
Other languages
English (en)
Other versions
MXPA98003801A (es
Inventor
Eero Vuorio
George Martin
Thomas B Neff
Leena Ala-Kokko
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MX9803801A publication Critical patent/MX9803801A/es
Publication of MXPA98003801A publication Critical patent/MXPA98003801A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a colágenas novedosas, secuencias de polinucleotidos que codifican estas proteínas novedosas, y al uso de estas proteínas novedosas y polinucleotidos en el diagnostico y tratamiento de enfermedades. La presente invencion se refiere además a colágenas específicas y derivados, específicamente proteínas de fusion de colágena de tipo IX con colágenos de tipo II y/o de tipo XI, y su uso como agentes terapéuticos.
MXPA/A/1998/003801A 1995-11-13 1998-05-13 Colagena de tipo ix y quimeras MXPA98003801A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US660895P 1995-11-13 1995-11-13
US006608 1995-11-13
US74553996A 1996-11-12 1996-11-12
US745539 2003-12-29

Publications (2)

Publication Number Publication Date
MX9803801A true MX9803801A (es) 1998-10-31
MXPA98003801A MXPA98003801A (es) 1999-01-11

Family

ID=

Also Published As

Publication number Publication date
BR9611547A (pt) 1999-06-15
EP0861086A1 (en) 1998-09-02
NO982181D0 (no) 1998-05-13
NO982181L (no) 1998-07-06
IL124437A0 (en) 1998-12-06
WO1997017988A1 (en) 1997-05-22
JP2001510981A (ja) 2001-08-07
CA2237900A1 (en) 1997-05-22

Similar Documents

Publication Publication Date Title
WO1996034953A3 (en) Cd16-ii variants
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
CA2257133A1 (en) Human dnase i hyperactive variants
CA2259163A1 (en) Nt-3 and bdnf analogs having improved circulating life and/or absorption
EA199801044A1 (ru) Модуляторы регенерации тканей
EP0849361A3 (en) Novel ligands of the neuropeptide receptor HFGAN72
EP0815202A4 (en) HUMAN TISSUE INHIBITOR OF METALLOPROTEINASE-4
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
NO982181L (no) Type IX collagen og chimerer
EP0330396A3 (en) Dna sequences, recombinant dna molecules and processes for producing lipocortins iii, iv, v & vi
ITBO930059A0 (it) Procedimento per ottenere la rigenerazione dei tessuti nella terapia odontoiatrica parodentale.
HUP0003116A2 (hu) Béta-amiloid-peptid-kötő fehérjék és az őket kódoló polinukleotidok
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
PT870036E (pt) Α-n-acetilglucosaminidase de mamífero sintética e sequências genéticas codificando a mesma
ATE343633T1 (de) Allele formen von menschlichem stat3
WO1999030670A3 (en) Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
BG105682A (en) Bone stimulating factor
DE69730967D1 (en) Human dnase ii
WO2002026980A3 (en) Human ion-exchanger proteins and polynucleotides encoding t he same
WO2002010380A1 (fr) Nouveau polypeptide, proteine a doigt de zinc de type kruppel zk110.12, et polynucleotide codant ce polypeptide
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide
CA2200846A1 (en) Promoter for the receptor tyrosine kinase, tie
ATE94759T1 (de) Verwendung von dextransulfat, gegebenenfalls in kombination mit anti-androgenen mitteln zur behandlung des humanen protatakarzinoms.